CAY10602 is a potent and selective SIRT1 activator identified via high-throughput screening. It dose-dependently inhibits NF-kappaB signaling and TNF-alpha production, as demonstrated in LPS-stimulated THP-1 cell assays with ~75% inhibition at 60 µM. This compound is a valuable research tool for studying SIRT1s role in inflammation, aging, and metabolic pathways in vitro.